Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 04, 2025, titled "Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market".
Press Release Sep 04 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a press release regarding an exclusive licensing and supply agreement with Synthon for Ozanimod Capsules, a generic version of ZEPOSIA, intended for the U.S. market. The agreement outlines that Synthon will handle regulatory approval and manufacturing, while Zydus will manage commercialization in the U.S. This collaboration aims to enhance access to essential medicines for patients with relapsing forms of multiple sclerosis.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. market
- Press Release Sep 02 2025
- Press Release Aug 29 2025
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
- Press Release 20-08-2025 Newspaperadvertisement20082025
Later from Zydus Lifesciences
- Press Release Sep 05 2025
- Press Release Sep 15 2025
- Zydus Lifesciences Limited Press Release Sep 21 2025
- Press Release Sep 23 2025
- Press Release Oct 01 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences